Citation Report
List of articles citing

First clinical experience with the new once-daily formulation of tacrolimus

DOI: 10.1097/ftd.0b013e318167909a
Therapeutic Drug Monitoring, 2008, 30, 159-66.

#	Paper	IF	Citations
53	Different preparations of tacrolimus and medication errors. *American Journal of Transplantation*, **2008**, 8, 1962	8.7	3
52	Immunosuppressive therapy in lung transplantation: state of the art. *European Journal of Cardio-thoracic Surgery*, **2009**, 35, 1045-55	3	19
51	De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. *Transplantation Proceedings*, **2009**, 41, 2115-7	1.1	66
50	Modified release tacrolimus in de novo immunosuppression after simultaneous pancreas-kidney transplantation--a first single-center experience. *Transplantation Proceedings*, **2009**, 41, 2573-5	1.1	7
49	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. *Therapeutic Drug Monitoring*, **2009**, 31, 139-52	3.2	347
48	Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. *Transplantation*, **2010**, 90, 523-9	1.8	68
47	Immunsuppression: neue Entwicklungen. *Der Nephrologe*, **2010**, 5, 133-141	0.1	
46	Conversion of heart transplant patients from standard to sustained-release tacrolimus requires a dosage increase. *Transplantation Proceedings*, **2010**, 42, 2994-6	1.1	12
45	[Current status of heart transplantation in Spain]. *Revista Espanola De Cardiologia*, **2010**, 63 Suppl 1, 132-49	1.3	10
44	Once- versus twice-daily tacrolimus: are the formulations truly equivalent?. *Drugs*, **2011**, 71, 1561-77	12.1	78
43	Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. *Transplantation Proceedings*, **2011**, 43, 491-4	1.1	20
42	Improved kidney graft function after conversion from twice daily tacrolimus to a once daily prolonged-release formulation. *Transplantation Proceedings*, **2011**, 43, 2950-3	1.1	26
41	Once-daily tacrolimus in living donor liver transplant recipients. *BioScience Trends*, **2011**, 5, 156-8	9.9	3
40	Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. *Transplantation*, **2011**, 92, 648-52	1.8	84
39	Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation. *Transplantation Proceedings*, **2011**, 43, 1028-9	1.1	12
38	Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome. *Transplantation Proceedings*, **2011**, 43, 3702-7	1.1	9
37	Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. *European Journal of Drug Metabolism and Pharmacokinetics*, **2011**, 36, 25-33	2.7	7

36	Pharmacokinetics of tacrolimus converted from twice-daily formulation to once-daily formulation in Chinese stable liver transplant recipients. *Acta Pharmacologica Sinica*, **2011**, 32, 1419-23	8	5
35	Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. *International Journal of Nephrology*, **2011**, 2011, 126251	1.7	11
34	Conversion of stable kidney transplant recipients from a twice-daily prograf to a once-daily tacrolimus formulation: a short-term study on its effects on glucose metabolism. *Transplantation Proceedings*, **2012**, 44, 128-33	1.1	16
33	Limited sampling strategy using Bayesian estimation for estimating individual exposure of the once-daily prolonged-release formulation of tacrolimus in kidney transplant children. *European Journal of Clinical Pharmacology*, **2013**, 69, 1181-5	2.8	11
32	Clinical outcome in cardiac transplant recipients receiving tacrolimus retard. *Transplantation Proceedings*, **2013**, 45, 2000-4	1.1	6
31	Tacrolimus effects and side effects after liver transplantation: is there a difference between immediate and extended release?. *Transplantation Proceedings*, **2013**, 45, 2321-5	1.1	8
30	Development and validation of limited sampling strategies for the estimation of mycophenolic acid area under the curve in adult kidney and liver transplant recipients receiving concomitant enteric-coated mycophenolate sodium and tacrolimus. *Therapeutic Drug Monitoring*, **2013**, 35, 760-9	3.2	13
29	Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. *Transplantation*, **2014**, 97, 358-62	1.8	13
28	Effects of converting tacrolimus formulation from twice-daily to once-daily in liver transplantation recipients. *BioMed Research International*, **2014**, 2014, 265658	3	4
27	Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. *Transplantation Proceedings*, **2014**, 46, 3117-20	1.1	9
26	Safety and efficacy of once-daily modified-release tacrolimus in kidney transplant recipients: interim analysis of multicenter postmarketing surveillance in Japan. *Transplantation Proceedings*, **2014**, 46, 406-10	1.1	7
25	Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover study. *Clinical Therapeutics*, **2014**, 36, 748-59	3.5	37
24	Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet. *European Journal of Pharmaceutical Sciences*, **2014**, 54, 1-7	5.1	33
23	Nonadherence, Psychosocial Adaptation and Its Effects in Pediatric Transplantation. **2014**, 1453-1474		
22	Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. *Transplantation Proceedings*, **2014**, 46, 749-53	1.1	7
21	Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. *Clinical Pharmacokinetics*, **2015**, 54, 993-1025	6.2	64
20	Pharmacokinetics for once-daily modified release formulation of tacrolimus hydrate in unrelated hematopoietic stem cell transplantation. *Annals of Hematology*, **2015**, 94, 491-6	3	7
19	Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. *Liver Transplantation*, **2016**, 22, 1391-400	4.5	14

18	Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. *Transplantation Proceedings*, **2016**, 48, 2276-2279	1.1	3
17	A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes. *PLoS ONE*, **2019**, 14, e0218709	3.7	2
16	Long-term Glomerular Filtration Rate and Kidney Disease: Improving Global Outcomes Stage Stability After Conversion to Once-Daily Tacrolimus in Kidney Transplant Recipients. *Transplantation Proceedings*, **2019**, 51, 147-152	1.1	3
15	Early Versus Late Conversion From Immediate to Prolonged-Release Tacrolimus After Renal Transplantation: Clinical Effects and Treatment Costs. *Transplantation Direct*, **2019**, 5, e417	2.3	
14	Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study. *Asian Journal of Surgery*, **2020**, 43, 660-667	1.6	5
13	Evaluation of the impact of Tacrolimus-based immunosuppression on Heidelberg liver transplant cohort (HDTACRO): Study protocol for an investigator initiated, non-interventional prospective study. *Medicine (United States)*, **2020**, 99, e22180	1.8	
12	Impacts of High Intra- and Inter-Individual Variability in Tacrolimus Pharmacokinetics and Fast Tacrolimus Metabolism on Outcomes of Solid Organ Transplant Recipients. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
11	Conversion From a Twice-Daily to a Once-Daily Tacrolimus Formulation in Kidney Transplant Recipients. *Transplantation Proceedings*, **2020**, 52, 2288-2293	1.1	2
10	Clinical Management. **2012**, 2515-2555		2
9	Safety and Efficacy of Once-Daily Prolonged-Release Tacrolimus in Living Donor Liver Transplantation: An Open-Label, Prospective, Single-Arm, Phase 4 Study. *Annals of Transplantation*, **2018**, 23, 713-720	1.4	3
8	Immunosuppression with tacrolimus early after orthotopic heart transplantation: a comparison of prograf and advagraf. *Heart Surgery Forum*, **2012**, 15, E307-9	0.7	7
7	Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up. *Central European Journal of Urology*, **2013**, 66, 344-9	0.9	5
6	Overview of extended release tacrolimus in solid organ transplantation. *World Journal of Transplantation*, **2016**, 6, 144-54	2.3	16
5	Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature. *Experimental and Clinical Transplantation*, **2014**, 12, 323-7	0.8	5
4	Pediatric Transplantation. **2012**, 2694-2718		
3	Conversion from Twice-Daily to Once-Daily Tacrolimus Improves Graft Function but has no Influence on Proteinuria in Renal Transplant Recipients. *BANTAO Journal*, **2016**, 14, 73-76		
2	A Comparative Analysis of Once-daily and Twice-daily Formulation of Tacrolimus in De Novo Kidney Transplant Recipients. *Sisli Etfal Hastanesi Tip Bulteni*, **2021**, 55, 62-67	0.8	0
1	Immunosuppression, Compliance, and Tolerance After Orthotopic Liver Transplantation: State of the Art.. *Experimental and Clinical Transplantation*, **2022**, 20, 3-9		